Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. This individual will be responsible for branded & disease education marketing, brand planning, and other pre-launch & launch initiatives ahead of the expansion of the franchise in late 2025. The ideal candidate has a versatile range of marketing skills and seamlessly collaborates with stakeholders across functions in a nimble, fast-paced environment.